-- Reported promising preliminary data from Phase 2 study of XmAb®5871 in IgG4-Related Disease (IgG4-RD) ----Announced strategic collaboration with Novartis for bispecific antibodies---- Robust cash position supports operations beyond 2020 ---- Management to host conference call today at 4:30 p.m. ET --
MONROVIA, Calif. , Feb. 22, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release fourth quarter and
MONROVIA, Calif. , Feb. 18, 2017 /PRNewswire/ -- Xencor , Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that investigators John H.
MONROVIA, Calif. , Feb. 9, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat , Ph.D.,
MONROVIA, Calif. , Dec. 6, 2016 /PRNewswire/ -- Xencor, Inc. ( NASDAQ : XNCR) today announced the completion of an underwritten public offering of 5,272,750 shares of its common stock, including 687,750 shares sold pursuant to the full exercise of an option previously granted to the underwriters to
MONROVIA, Calif. , Dec. 1, 2016 /PRNewswire/ -- Xencor, Inc. ( NASDAQ : XNCR) today announced the pricing of an underwritten public offering of 4,585,000 shares of its common stock, offered at a price to the public of $24.00 per share. The gross proceeds from this offering to Xencor are expected
MONROVIA, Calif. , Nov. 30, 2016 /PRNewswire/ -- Xencor, Inc. ( NASDAQ : XNCR) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Xencor expects to grant the underwriters a 30-day option to
- 9 of 11 patients (82%) achieved an initial response to therapy within 2 weeks of first dose --- 5 patients have attained disease remission (an IgG4-RD Responder Index of 0) -- Every other week intravenous administration of XmAb5871 in patients with active IgG4-RD has been well tolerated -- Xencor management to host conference call today at 6:00 p.m. EST -
MONROVIA, Calif. , Nov. 11, 2016 /PRNewswire/ -- Xencor, Inc. ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that data from preclinical
